Search Results for "Recall Promus Heart Stent"

18:13 EDT 28th March 2015 | BioPortfolio

Matching Channels

BioMimics 3D™ Stent

Veryan has developed three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The initial objective was to investigate the presen...

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Aorfix

Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anat...

Heart Transplantation

Heart Failure HF

Matching News

Added Value of Biodegradable-Polymer DES Questioned

Researchers said they saw no advantage against late stent thrombosis for the biodegradable-polymer Nobori stent. In a different study, the Synergy stent was noninferior to the Promus Prime DES. Hear...

Boston Scientific's Synergy stent passes Evolve II trial

Boston Scientific's Synergy stent passed the Evolve II trial, where it was put against drug-eluting stent Promus, the company -More- 

Boston Scientific Launches Stent Trial In Underserved Populations

PLATINUM Diversity trial will examine Promus Premier stent in women and people of color, populations that have been underrepresented in previous trials. The trial coincides with the company’s Close ...

Extended anti-clotting therapy cut heart attacks after stent -study

CHICAGO, Nov 16 (Reuters) - Patients who took two anti-clotting drugs for 30 months after undergoing a heart stent placement significantly cut their risk of heart attacks and blood clots in the stent ...

Heart Sync's defibrillator electrode recall labeled Class I by FDA

A recall initiated by Michigan firm Heart Sync on Nov.  -More- 

Extended post-stent treatment reduces risk of coronary thrombosis

Patients who took two anti-clotting medications beyond the standard 12 months after stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack ...

Boston Scientific stent succeeds in study aimed at U.S. approval

CHICAGO, Nov 19 (Reuters) - Boston Scientific Corp's next generation Synergy heart stent succeeded in a pivotal study that will be used to seek U.S. and Japanese approval of the device, according to d...

Causes, assessment, and treatment of stent thrombosis—intravascular imaging insights

Stent thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In this Review, Ong and Jang discuss the use of intra...

Matching PubMed Articles

Outcomes of everolimus-eluting stent incomplete stent apposition: a serial optical coherence tomography analysis.

The aim of the present study was to evaluate the natural course of acute incomplete stent apposition (ISA) after second-generation everolimus-eluting stent (EES) when compared with first-generation si...

PLATINUM China: A prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.

Objectives: The PLATINUM China clinical trial evaluated the safety and effectiveness of the thin-strut, everolimus-eluting, platinum-chromium PROMUS™ Element™ stent (PtCr-EES) (Boston Scientific, ...

Spectral Analysis Related to Bare-Metal and Drug-Eluting Coronary Stent Implantation.

Background: The autonomic nervous system plays a central role in cardiovascular regulation; sympathetic activation occurs during myocardial ischemia. Objective: To assess the spectral analysis of hear...

Bioresorbable vascular scaffold for coronary in-stent restenosis: A novel concept.

The management of patients with significant in-stent restenosis (ISR) with drug-eluting stent is still not well defined. Various treatment modalities include plain old balloon angioplasty (POBA), meta...

Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history.

There has been an increasing trend in the number of prescribed and over-the-counter drug recall over the last few years. The recall is usually due to company's discovery, customer's complaint or Food ...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement